$87.1 Million is the total value of Casdin Capital, LLC's 26 reported holdings in Q1 2016. The portfolio turnover from Q4 2015 to Q1 2016 was 50.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| EPZM | Buy | EPIZYME INC | $6,605,000 | +24.0% | 545,000 | +63.9% | 7.58% | +61.1% |
| FMI | Buy | FOUNDATION MEDICINE INC | $6,090,000 | +151.4% | 335,000 | +191.3% | 6.99% | +226.6% |
| SAGE | Buy | SAGE THERAPEUTICS INC | $6,059,000 | -27.3% | 189,000 | +32.2% | 6.95% | -5.6% |
| AGIO | Buy | AGIOS PHARMACEUTICALS INC | $6,009,000 | -4.1% | 148,000 | +53.4% | 6.90% | +24.6% |
| ALNY | Buy | ALNYLAM PHARMACEUTICALS INC | $5,649,000 | +0.0% | 90,000 | +50.0% | 6.48% | +29.9% |
| BLUE | Buy | BLUEBIRD BIO INC | $5,100,000 | -20.6% | 120,000 | +20.0% | 5.85% | +3.2% |
| MYOK | Buy | MYOKARDIA INC | $5,091,000 | -14.0% | 475,350 | +17.7% | 5.84% | +11.7% |
| ONCE | Buy | SPARK THERAPEUTICS INC | $5,017,000 | -23.6% | 170,000 | +17.2% | 5.76% | -0.8% |
| KITE | Buy | KITE PHARMA INC | $3,443,000 | +86.2% | 75,000 | +150.0% | 3.95% | +141.9% |
| VYGR | Buy | VOYAGER THERAPEUTICS INC | $2,963,000 | -42.9% | 339,362 | +43.3% | 3.40% | -25.8% |
| EDIT | New | EDITAS MEDICINE INC | $2,952,000 | – | 85,470 | +100.0% | 3.39% | – |
| DXCM | Buy | DEXCOM INC | $2,716,000 | +95.1% | 40,000 | +135.3% | 3.12% | +153.4% |
| XBI | New | SPDR SERIES TRUSTput | $2,583,000 | – | 50,000 | +100.0% | 2.96% | – |
| AVXS | New | AVEXIS INC | $1,716,000 | – | 63,000 | +100.0% | 1.97% | – |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS IN | $1,665,000 | -20.8% | 105,000 | +61.5% | 1.91% | +3.0% |
| BGNE | New | BEIGENE LTDsponsored adr | $953,000 | – | 32,500 | +100.0% | 1.09% | – |
| RXDX | New | IGNYTA INC | $745,000 | – | 110,000 | +100.0% | 0.86% | – |
| EXAS | New | EXACT SCIENCES CORP | $404,000 | – | 60,000 | +100.0% | 0.46% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-05-09
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BLUEPRINT MEDICINES CORP | 32 | Q3 2023 | 9.6% |
| ALNYLAM PHARMACEUTICALS INC | 32 | Q3 2023 | 9.9% |
| AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
| GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
| FATE THERAPEUTICS INC | 26 | Q3 2023 | 8.3% |
| BIOLIFE SOLUTIONS INC | 22 | Q3 2023 | 14.9% |
| CODEXIS INC | 22 | Q3 2023 | 8.1% |
| SAREPTA THERAPEUTICS INC | 21 | Q3 2023 | 13.6% |
| BLUEBIRD BIO INC | 21 | Q4 2020 | 7.8% |
| ILLUMINA INC | 21 | Q3 2023 | 6.0% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
| CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Tango Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Verve Therapeutics, Inc. | February 14, 2023 | 2,290,571 | 3.7% |
| Tenaya Therapeutics, Inc. | December 07, 2022 | 6,427,200 | 9.9% |
| Fulcrum Therapeutics, Inc. | February 11, 2021 | 1,241,176 | 4.5% |
| Gritstone Oncology, Inc.Sold out | February 11, 2021 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-02 |
| SC 13G | 2024-04-18 |
| SC 13D/A | 2024-04-08 |
| 4 | 2024-03-28 |
| 3 | 2024-03-25 |
| 4 | 2024-03-25 |
| 4 | 2024-03-20 |
| SC 13D/A | 2024-03-20 |
| 4 | 2024-03-06 |
| 4 | 2024-03-06 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.